Geomatrix is a registered trademark of Jagotec AG. Shionogi Pharma’s use of the Geomatrix technology is under license from SkyePharma.
Shionogi Pharma, Inc. (formerly Sciele Pharma, Inc.) is a US-based group company of Shionogi & Co., Ltd. Shionogi Pharma is based in Atlanta, Georgia and specializes in sales, marketing and development of branded prescription products focused on Cardiovascular/Diabetes, Women's Health and Pediatrics. The Company's Cardiovascular/Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and type 2 diabetes; its Women's Health products are designed to improve the health and well-being of women and mothers and their babies; and its Pediatrics products treat allergies, asthma, head lice infestations, and attention deficit/hyperactivity disorder (ADHD).
Shionogi & Co., Ltd., headquartered in Osaka, Japan, is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi's Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic Syndrome. The Company has provided innovative medicines such as Crestor and Doripenem, which have been successfully delivered to millions of patients. In addition, Shionogi is engaged in research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit www.shionogi.co.jp.
Phone:
Customer Support
(800) 461-3696
Medical Affairs:
(For Medical Information/Adverse Events/ Product Complaints)
(800) 849-9707 ext 1454
Mailing Address:
Shionogi Pharma, Inc.
5 Concourse Pkwy.
Suite 1800
Atlanta, Georgia 30328
Indication:
SULAR is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Important Safety Information:
The most common adverse events, reported in US placebo-controlled trials, were peripheral edema, headache, and dizziness. In rare cases, some patients, particularly those with severe obstructive coronary artery disease, have developed increased frequency, duration, and/or severity of
angina, or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase. Safety of SULAR in patients with heart failure has not been established. SULAR should be administered cautiously in patients over the age of 65 and in those with severe
hepatic dysfunction. Because nisoldipine, like other vasodilators, decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of SULAR is recommended. SULAR should not be taken with grapefruit products.
Please click here for full prescribing information.
Your Healthcare Provider can give you more information about Sular or call (800) 849-9707 ext 1454. Ask your Healthcare Provider if Sular may be right for you.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
Images are for illustrative purposes only.
© 2008 Shionogi Pharma, Inc.
This web site and its contents are intended for use only by residents of the United States. Products discussed may have different labeling, regulatory requirements, and/or medical practices in other countries that may require reference to different or additional information.